Neraxiva Men S Intimate Care (Moisture Care Cream)

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Neraxiva Men S Intimate Care (Moisture Care Cream)
Generic name
SULPHUR
Manufacturer
Guangdong Xinhongda Trading Service Co., Ltd.
Product type
HUMAN OTC DRUG
SPL set ID
58e8c35d-219b-02fd-e063-6294a90a9f90
SPL ID
58e8c35d-219c-02fd-e063-6294a90a9f90
Version
1
Effective date
2026-08-13
Source export date
2026-09-28
Source partition
2
Source file
https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-09-28/f7d2b6e3f8600cd856280ab55a9c6fa54a642647191d164f9d1110e89f3f4097/drug-label-0002-of-0014.json.zip
Source manifest SHA-256
cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run
20260929T050834Z
Imported at
2026-09-29 05:15:29
Harmonized routes table
Harmonized routes
TOPICAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warning For external use only. For adult use only. Test on a small area of external skin before first use. Avoid contact with eyes, internal areas and broken or severely irritated skin. Keep out of reach of children. If a skin concern persists or worsens, consult a healthcare professional. Do not use in children under 18 years of age. if sensitive to any ingredient. inside the urethral opening or to internal or mucosal areas. on broken, bleeding or severely irritated skin. Stop Using and ask a doctor if burning, redness, swelling or discomfort occurs. When Using this product avoid contact with eyes, nose, and mouth. If contact occurs, rinse thoroughly with water.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.